Jean Mironneau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jean Mironneau has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chantal Mironneau
Laboratoire de Signalisation et Interactions Cellulaires, Université de Bordeaux, Bordeaux, France
2 shared publications- Nathalie Macrez
Laboratoire de Physiologie Cellulaire et Pharmacologie Moléculaire, CNRS ESA 5017, Université de Bordeaux II, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
2 shared publications Catherine Leblanc
Laboratoire de Signalisation et Interactions Cellulaires, Université de Bordeaux, Bordeaux, France
1 shared publicationLala Rakotoarisoa
Laboratoire de Signalisation et Interactions Cellulaires, Université de Bordeaux, Bordeaux, France
1 shared publicationPatricia Viard
Laboratoire de Signalisation et Interactions Cellulaires, CNRS UMR 5017, Université de Bordeaux II, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
1 shared publicationValérie Carricaburu
Laboratoire de Signalisation et Interactions Cellulaires, Université de Bordeaux, Bordeaux, France
1 shared publication
Latest Publications
- Open Access
- 1 July 2006
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 10 (3) , 734-748
Angiotensin II-induced delayed stimulation of phospholipase C ?1 requires activation of both phosphatidiylinositol 3-kinase ? and tyrosine kinase in vascular myocytes
In vascular smooth muscles, angiotensin II (AII) has been reported to activate phospholipase C (PLC) and phosphatidylinositol 3-kinase (PI3K). We investigated the time-dependent effects of AII on both phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3) and inositol phosphates (InsPs) accumulation in permeabilized microsomes from rat portal vein smooth muscle in comparison with those of noradrenaline (NA). AII stimulated an early production of PtdInsP3 (within 30 s) followed by a delayed production of InsPs (within 3-5 min), in contrast to NA which activated only a fast production of InsPs. The use of pharmacological inhibitors and antibodies raised against the PI3K and PLC isoforms expressed in portal vein smooth muscle showed that AII specifically activated PI3Kδ and that this isoform was involved in the AII-induced stimulation of InsPs accumulation. NA-induced InsPs accumulation depended on PLCβ1 activation whereas AII-induced InsPs accumulation depended on PLCγ1 activation. AII-induced PLCδ1 activation required both tyrosine kinase and PI3Kδ since genistein and tyrphostin B48 (inhibitors of tyrosine kinase), LY294002 and wortmannin (inhibitors of PI3K) and anti-PI3Kδ antibody abolished AII-induced stimulation of InsPs accumulation. Increased tyrosine phosphorylation of PLCβ1 was only detected for long-lasting applications of AII and was suppressed by genistein. These data indicate that activation of both PI3Kβ and tyrosine kinase is a prerequisite for AII-induced stimulation of PLCβ1 in vascular smooth muscle and suggest that the sequential activation of the three enzymes may be responsible for the slow and long-lasting contraction induced by AII.
- 1 July 2006
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 10 (3) , 734-748
Open AccessAngiotensin II-induced delayed stimulation of phospholipase C ?1 requires activation of both phosphatidiylinositol 3-kinase ? and tyrosine kinase in vascular myocytes
In vascular smooth muscles, angiotensin II (AII) has been reported to activate phospholipase C (PLC) and phosphatidylinositol 3-kinase (PI3K). We investigated the time-dependent effects of AII on both phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3) and inositol phosphates (InsPs) accumulation in permeabilized microsomes from rat portal vein smooth muscle in comparison with those of noradrenaline (NA). AII stimulated an early production of PtdInsP3 (within 30 s) followed by a delayed production of InsPs (within 3-5 min), in contrast to NA which activated only a fast production of InsPs. The use of pharmacological inhibitors and antibodies raised against the PI3K and PLC isoforms expressed in portal vein smooth muscle showed that AII specifically activated PI3Kδ and that this isoform was involved in the AII-induced stimulation of InsPs accumulation. NA-induced InsPs accumulation depended on PLCβ1 activation whereas AII-induced InsPs accumulation depended on PLCγ1 activation. AII-induced PLCδ1 activation required both tyrosine kinase and PI3Kδ since genistein and tyrphostin B48 (inhibitors of tyrosine kinase), LY294002 and wortmannin (inhibitors of PI3K) and anti-PI3Kδ antibody abolished AII-induced stimulation of InsPs accumulation. Increased tyrosine phosphorylation of PLCβ1 was only detected for long-lasting applications of AII and was suppressed by genistein. These data indicate that activation of both PI3Kβ and tyrosine kinase is a prerequisite for AII-induced stimulation of PLCβ1 in vascular smooth muscle and suggest that the sequential activation of the three enzymes may be responsible for the slow and long-lasting contraction induced by AII.
- Open Access
- 1 February 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (3) , 669-676
Involvement of both G protein αs and βγ subunits in β‐adrenergic stimulation of vascular L‐type Ca2+ channels
Previous data have shown that activation of β3‐adrenoceptors stimulates vascular L‐type Ca2+ channels through a Gαs‐induced stimulation of the cyclic AMP/PKA pathway. The present study investigated whether β‐adrenergic stimulation also uses the Gβγ/PI3K/PKC pathway to modulate L‐type Ca2+ channels in rat portal vein myocytes. Peak Ba2+ current (IBa) measured using the whole‐cell patch clamp method was maximally increased by application of 10 μM isoprenaline after blockade of β3‐adrenoceptors by 1 μM SR59230A. Under these conditions, the isoprenaline‐induced stimulation of IBa was reversed by ICI‐118551 (a specific β2‐adrenoceptor antagonist) but not by atenolol (a specific β1‐adrenoceptor antagonist). The β2‐adrenoceptor agonist salbutamol increased IBa, an effect which was reversed by ICI‐118551 whereas the β1‐adrenoceptor agonist dobutamine had no effect on IBa. Application of PKA inhibitors (H‐89 and Rp 8‐Br‐cyclic AMPs) or a PKC inhibitor (calphostin C) alone did not affect the β2‐adrenergic stimulation of IBa whereas simultaneous application of both PKA and PKC inhibitors completely blocked this stimulation. The β2‐adrenergic stimulation of L‐type Ca2+ channels was blocked by a pre‐treatment with cholera toxin and by intracellular application of an anti‐Gαs antibody (directed against the carboxyl terminus of Gαs). In the presence of H‐89, intracellular infusion of an anti‐Gβcom antibody or a βARK1 peptide as well as a pre‐treatment with wortmannin (a PI3K inhibitor) blocked the β2‐adrenergic stimulation of IBa. These results suggest that the β2‐adrenergic stimulation of vascular L‐type Ca2+ channels involves both Gαs and Gβγ subunits which exert their stimulatory effects through PKA and PI3K/PKC pathways, respectively. British Journal of Pharmacology (2001) 132, 669–676; doi:10.1038/sj.bjp.0703864
- 1 February 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (3) , 669-676
Open AccessInvolvement of both G protein αs and βγ subunits in β‐adrenergic stimulation of vascular L‐type Ca2+ channels
Previous data have shown that activation of β3‐adrenoceptors stimulates vascular L‐type Ca2+ channels through a Gαs‐induced stimulation of the cyclic AMP/PKA pathway. The present study investigated whether β‐adrenergic stimulation also uses the Gβγ/PI3K/PKC pathway to modulate L‐type Ca2+ channels in rat portal vein myocytes. Peak Ba2+ current (IBa) measured using the whole‐cell patch clamp method was maximally increased by application of 10 μM isoprenaline after blockade of β3‐adrenoceptors by 1 μM SR59230A. Under these conditions, the isoprenaline‐induced stimulation of IBa was reversed by ICI‐118551 (a specific β2‐adrenoceptor antagonist) but not by atenolol (a specific β1‐adrenoceptor antagonist). The β2‐adrenoceptor agonist salbutamol increased IBa, an effect which was reversed by ICI‐118551 whereas the β1‐adrenoceptor agonist dobutamine had no effect on IBa. Application of PKA inhibitors (H‐89 and Rp 8‐Br‐cyclic AMPs) or a PKC inhibitor (calphostin C) alone did not affect the β2‐adrenergic stimulation of IBa whereas simultaneous application of both PKA and PKC inhibitors completely blocked this stimulation. The β2‐adrenergic stimulation of L‐type Ca2+ channels was blocked by a pre‐treatment with cholera toxin and by intracellular application of an anti‐Gαs antibody (directed against the carboxyl terminus of Gαs). In the presence of H‐89, intracellular infusion of an anti‐Gβcom antibody or a βARK1 peptide as well as a pre‐treatment with wortmannin (a PI3K inhibitor) blocked the β2‐adrenergic stimulation of IBa. These results suggest that the β2‐adrenergic stimulation of vascular L‐type Ca2+ channels involves both Gαs and Gβγ subunits which exert their stimulatory effects through PKA and PI3K/PKC pathways, respectively. British Journal of Pharmacology (2001) 132, 669–676; doi:10.1038/sj.bjp.0703864